ResMed Inc. director Desney Tan reported receiving a new equity award from the company. On 11/20/2025, he acquired 1,073 shares of ResMed common stock through a grant priced at $0, increasing his directly owned stake to 6,002 shares after the transaction.
The award is in the form of restricted stock units (RSUs), which are shares that Tan will receive once they vest. These RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, meaning the shares are subject to a service-based vesting condition tied to time and board tenure.
ResMed Inc. (RMD) reported that director Harjit Gill received an equity award in the form of 1,073 restricted stock units (RSUs) of ResMed common stock on 11/20/2025. The RSUs were granted at a price of $0 per unit, reflecting a typical director equity grant rather than an open‑market purchase.
After this award, Gill beneficially owns 10,940 shares of ResMed common stock. The RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, tying the equity award to continued board service over roughly a one‑year cycle.
ResMed Inc. (RMD) director Carol Burt reported a grant of 1,073 shares of ResMed common stock in the form of restricted stock units. These RSUs were awarded on 11/20/2025 at a price of $0 per share, reflecting a typical equity compensation grant for a board member rather than an open-market purchase.
Following this award, she reported 2,156 shares of ResMed common stock held directly and an additional 16,660 shares held indirectly through the Carol Burt Hilliard Trust. The RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, tying the equity award to her continued board service.
ResMed Inc. (RMD) reported a change in director ownership through a Form 4 filing. Director Ronald Taylor received an award of 1,073 shares of ResMed common stock on 11/20/2025 at a stated price of $0, reflecting a grant rather than an open-market purchase. Following this transaction, he beneficially owns 24,771 shares directly.
The shares awarded are in the form of Restricted Stock Units (RSUs). These RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, aligning the director’s compensation with the company’s long-term performance and shareholder interests.
ResMed Inc. (RMD) Chief Financial Officer Brett Sandercock reported an equity award vesting. On 11/20/2025, he acquired 2,710 shares of ResMed common stock at a price of $0 per share, reflecting the earning of performance-based restricted stock units originally granted on 11/16/2022. The compensation and leadership development committee certified that the required performance metrics were met, which triggered the share delivery.
Following this transaction, Sandercock beneficially owns 88,495 shares of ResMed common stock in direct ownership. This filing is a routine disclosure of insider equity compensation vesting and does not indicate an open-market purchase or sale.
ResMed Inc. (RMD) Chairman and CEO Michael J. Farrell reported routine equity compensation activity. On 11/20/2025, he acquired 13,551 shares of ResMed common stock at $0, following the earning of performance-based restricted stock units that were granted on November 16, 2022 and certified as earned by the compensation and leadership development committee.
On the same date, 7,297 shares were disposed of at $0 to ResMed to cover tax withholding on the vesting. After these transactions, Farrell beneficially owned 466,223 shares directly and 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust.
ResMed Inc. (RMD) reported an insider equity award for director Christopher DelOrefice. On 11/20/2025, he acquired 1,073 shares of ResMed common stock at a price of $0, reported as an award of restricted stock units. After this transaction, he beneficially owns 2,423 shares directly.
The filing notes that these restricted stock units (RSUs) vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, tying the award to continued board service.
ResMed Inc. director equity grant reported on Form 4. Director Jan De Witte reported receiving 1,073 shares of ResMed common stock in the form of restricted stock units on 11/20/2025 at a price of $0 per share. After this grant, De Witte beneficially owns 6,316 shares directly. The restricted stock units vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, aligning director compensation with the company’s long‑term performance.
ResMed Inc. (RMD) director Peter C. Farrell reported an equity award under a director compensation program. On 11/20/2025, he acquired 536 shares of ResMed common stock at a stated price of $0, reported as an acquisition of non-derivative securities. Following this transaction, he beneficially owned 70,773 shares held directly.
The filing explains that these shares were awarded in the form of Restricted Stock Units (RSUs). The RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, aligning the director’s compensation with shareholder interests over that period.
ResMed Inc. (RMD) reported insider information for director Richard Sulpizio on a Form 4. Following the reported activity, he beneficially owned 17,796 shares of ResMed common stock in direct ownership. The filing also notes that Sulpizio ceased to serve as a director at the conclusion of ResMed’s 2025 annual meeting of stockholders held on November 19, 2025, marking his departure from the company’s board.